Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,190 and keeps a Buy rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly price target raised to $1,080 from $895 at UBS
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly
- Eli Lilly GLP-1 pricing deal ‘probably a good tradeoff,’ says BofA
- GLP-1 price cuts limit Hims advantage, says Needham
- Eli Lilly confirms weight loss drug agreement with U.S. government